BACKGROUND: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). METHODS: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were treated with sunitinib. The primary end point was confirmed 50% prostate-specific antigen (PSA) decline. Secondary end points included objective response rate and safety. Serum-soluble biomarkers were measured. RESULTS: Seventeen men were enrolled in each group. One confirmed PSA response was observed in each group, and an additional eight men and seven men had stable PSA at week 12 in groups A and B, respectively. Improvements in imaging were observed in the absence of post-treatment PSA declines. Common adverse effects included fatigue, nausea, diarrhea, myelosuppression and transaminase elevation. Significant changes following sunitinib treatment were observed in serum-soluble biomarkers including soluble vascular endothelial growth factor receptor-2, platelet-derived growth factor aa, placental growth factor and leptin. CONCLUSIONS: Sunitinib monotherapy resulted in few confirmed 50% post-treatment declines in PSA in men with CRPC. Serum markers of angiogenesis confirmed on-target effects of sunitinib. Assessments of radiographic disease status were often discordant with changes in PSA, indicating that alternate end points are important in future trials.
BACKGROUND: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). METHODS:Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were treated with sunitinib. The primary end point was confirmed 50% prostate-specific antigen (PSA) decline. Secondary end points included objective response rate and safety. Serum-soluble biomarkers were measured. RESULTS: Seventeen men were enrolled in each group. One confirmed PSA response was observed in each group, and an additional eight men and seven men had stable PSA at week 12 in groups A and B, respectively. Improvements in imaging were observed in the absence of post-treatment PSA declines. Common adverse effects included fatigue, nausea, diarrhea, myelosuppression and transaminase elevation. Significant changes following sunitinib treatment were observed in serum-soluble biomarkers including soluble vascular endothelial growth factor receptor-2, platelet-derived growth factor aa, placental growth factor and leptin. CONCLUSIONS:Sunitinib monotherapy resulted in few confirmed 50% post-treatment declines in PSA in men with CRPC. Serum markers of angiogenesis confirmed on-target effects of sunitinib. Assessments of radiographic disease status were often discordant with changes in PSA, indicating that alternate end points are important in future trials.
Authors: Robert J Motzer; M Dror Michaelson; Bruce G Redman; Gary R Hudes; George Wilding; Robert A Figlin; Michelle S Ginsberg; Sindy T Kim; Charles M Baum; Samuel E DePrimo; Jim Z Li; Carlo L Bello; Charles P Theuer; Daniel J George; Brian I Rini Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg Journal: Clin Cancer Res Date: 2008-01-01 Impact factor: 12.531
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: K N Chi; S L Ellard; S J Hotte; P Czaykowski; M Moore; J D Ruether; A J Schell; S Taylor; C Hansen; I Gauthier; W Walsh; L Seymour Journal: Ann Oncol Date: 2007-12-03 Impact factor: 32.976
Authors: M R Sierra-Honigmann; A K Nath; C Murakami; G García-Cardeña; A Papapetropoulos; W C Sessa; L A Madge; J S Schechner; M B Schwabb; P J Polverini; J R Flores-Riveros Journal: Science Date: 1998-09-11 Impact factor: 47.728
Authors: Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer Journal: J Transl Med Date: 2007-07-02 Impact factor: 5.531
Authors: S Steinbild; K Mross; A Frost; R Morant; S Gillessen; C Dittrich; D Strumberg; A Hochhaus; A-R Hanauske; L Edler; I Burkholder; M Scheulen Journal: Br J Cancer Date: 2007-11-27 Impact factor: 7.640
Authors: Peter B Makhov; Konstantin Golovine; Alexander Kutikov; Ervin Teper; Daniel J Canter; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko Journal: Mol Cancer Ther Date: 2012-04-24 Impact factor: 6.261
Authors: Stefan Vallo; Jens Mani; Matthias Stastny; Jasmina Makarević; Eva Juengel; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta Journal: Invest New Drugs Date: 2012-07-17 Impact factor: 3.850
Authors: Sunil Parimi; Misha Eliasziw; Scott North; Marc Trudeau; Eric Winquist; Kim N Chi; Dean Ruether; Tina Cheng; Bernhard J Eigl Journal: Invest New Drugs Date: 2016-08-26 Impact factor: 3.850
Authors: P Ströbel; R Bargou; A Wolff; D Spitzer; C Manegold; A Dimitrakopoulou-Strauss; L Strauss; C Sauer; F Mayer; P Hohenberger; A Marx Journal: Br J Cancer Date: 2010-06-22 Impact factor: 7.640